Register a trial

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00479739




Registration number
NCT00479739
Ethics application status
Date submitted
25/05/2007
Date registered
28/05/2007

Titles & IDs
Public title
CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.
Scientific title
Randomised, Double-blind, Double-dummy, 52-week, Parallel Group Study of a Standard Dosing Regimen With Salmeterol/Fluticasone propionate50/250 Twice Daily Diskus Versus a Symptom-driven, Variable Dosing Regimen With Formoterol/Budesonide Combination 4.5/160 in Adult Asthmatics
Secondary ID [1] 0 0
SAM40056
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Arm 1 -

Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Mean percentage of symptom-free days over a 52-week treatment period
Timepoint [1] 0 0
Secondary outcome [1] 0 0
Mean percentage of rescue-free days Daily asthma symptom scores Daily rescue usage Mean morning peak flow Percentage of nights awoken due to asthma Rate of exacerbations Airway hyper-responsiveness(PC20 AMP)
Timepoint [1] 0 0

Eligibility
Key inclusion criteria
* Documented clinical history of asthma
* Forced expiratory volume in 1 second between 60% and 90% of predicted
* Using an inhaled corticosteroid (ICS)at a dose equivalent to 200 to 500 mcg daily of beclomethasone (BDP)or equivalent combined with a long-acting beta-2-agonist or an ICS alone at a dose equivalent to >500 to 1000mcg daily of BDP daily
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Lower respiratory tract infection within 1 month of study entry
* Use of systemic corticosteroids within 1 month of study entry
* Smoking history of 10 pack years or more Changes in regular asthma therapy within 12 weeks of study entry
* Any significant disorder that in the investigator's opinion might put the patient at risk or influence the study outcomes

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2002
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2004
Sample size
Target
Accrual to date
Final
700
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA
Recruitment hospital [1] 0 0
GSK Investigational Site - Balmain
Recruitment hospital [2] 0 0
GSK Investigational Site - Brisbane
Recruitment hospital [3] 0 0
GSK Investigational Site - Kippa Ring
Recruitment hospital [4] 0 0
GSK Investigational Site - Toorak Gardens
Recruitment postcode(s) [1] 0 0
2041 - Balmain
Recruitment postcode(s) [2] 0 0
4077 - Brisbane
Recruitment postcode(s) [3] 0 0
4021 - Kippa Ring
Recruitment postcode(s) [4] 0 0
5065 - Toorak Gardens
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Linz
Country [2] 0 0
Austria
State/province [2] 0 0
Vienna
Country [3] 0 0
Belgium
State/province [3] 0 0
Aalst
Country [4] 0 0
Belgium
State/province [4] 0 0
Ath
Country [5] 0 0
Belgium
State/province [5] 0 0
Gilly
Country [6] 0 0
Belgium
State/province [6] 0 0
Hornu
Country [7] 0 0
Belgium
State/province [7] 0 0
Leopoldsburg
Country [8] 0 0
Belgium
State/province [8] 0 0
Oostham
Country [9] 0 0
Belgium
State/province [9] 0 0
Tessenderlo
Country [10] 0 0
Belgium
State/province [10] 0 0
Tienen
Country [11] 0 0
Bulgaria
State/province [11] 0 0
Plovdiv
Country [12] 0 0
Bulgaria
State/province [12] 0 0
Rousse
Country [13] 0 0
Bulgaria
State/province [13] 0 0
Sofia
Country [14] 0 0
Bulgaria
State/province [14] 0 0
Varna
Country [15] 0 0
Canada
State/province [15] 0 0
Alberta
Country [16] 0 0
Canada
State/province [16] 0 0
British Columbia
Country [17] 0 0
Canada
State/province [17] 0 0
Manitoba
Country [18] 0 0
Canada
State/province [18] 0 0
New Brunswick
Country [19] 0 0
Canada
State/province [19] 0 0
Ontario
Country [20] 0 0
Canada
State/province [20] 0 0
Quebec
Country [21] 0 0
Estonia
State/province [21] 0 0
Kohtal-Jdrve
Country [22] 0 0
Estonia
State/province [22] 0 0
Tallinn
Country [23] 0 0
Estonia
State/province [23] 0 0
Tartu
Country [24] 0 0
Finland
State/province [24] 0 0
Joensuu
Country [25] 0 0
Finland
State/province [25] 0 0
Lahti
Country [26] 0 0
Finland
State/province [26] 0 0
Pietarsaari
Country [27] 0 0
Finland
State/province [27] 0 0
Raahe
Country [28] 0 0
Finland
State/province [28] 0 0
Tampere
Country [29] 0 0
Finland
State/province [29] 0 0
Varkaus
Country [30] 0 0
Germany
State/province [30] 0 0
Baden-Wuerttemberg
Country [31] 0 0
Germany
State/province [31] 0 0
Bayern
Country [32] 0 0
Germany
State/province [32] 0 0
Brandenburg
Country [33] 0 0
Germany
State/province [33] 0 0
Berlin
Country [34] 0 0
Ireland
State/province [34] 0 0
Blackpool, Cork
Country [35] 0 0
Ireland
State/province [35] 0 0
Dublin
Country [36] 0 0
Ireland
State/province [36] 0 0
Galway
Country [37] 0 0
Ireland
State/province [37] 0 0
Kilkenny
Country [38] 0 0
Ireland
State/province [38] 0 0
Lifford
Country [39] 0 0
Ireland
State/province [39] 0 0
Tallaght, Dublin
Country [40] 0 0
Latvia
State/province [40] 0 0
Limbazi
Country [41] 0 0
Latvia
State/province [41] 0 0
Riga
Country [42] 0 0
Latvia
State/province [42] 0 0
Valmiera
Country [43] 0 0
Macedonia, The Former Yugoslav Republic of
State/province [43] 0 0
Skopje
Country [44] 0 0
Netherlands
State/province [44] 0 0
's-HERTOGENBOSCH
Country [45] 0 0
Netherlands
State/province [45] 0 0
Almelo
Country [46] 0 0
Netherlands
State/province [46] 0 0
Bennebroek
Country [47] 0 0
Netherlands
State/province [47] 0 0
Eindhoven
Country [48] 0 0
Netherlands
State/province [48] 0 0
Geldermalsen
Country [49] 0 0
Netherlands
State/province [49] 0 0
Heerlen
Country [50] 0 0
Netherlands
State/province [50] 0 0
Helmond
Country [51] 0 0
Netherlands
State/province [51] 0 0
Losser
Country [52] 0 0
Netherlands
State/province [52] 0 0
Made
Country [53] 0 0
Netherlands
State/province [53] 0 0
Rotterdam
Country [54] 0 0
Netherlands
State/province [54] 0 0
Spijkenisse
Country [55] 0 0
Netherlands
State/province [55] 0 0
Utrecht
Country [56] 0 0
Netherlands
State/province [56] 0 0
Voerendaal
Country [57] 0 0
New Zealand
State/province [57] 0 0
Auckland
Country [58] 0 0
New Zealand
State/province [58] 0 0
Christchurch Hospital
Country [59] 0 0
Spain
State/province [59] 0 0
Alcorcon
Country [60] 0 0
Spain
State/province [60] 0 0
Barcelona
Country [61] 0 0
Spain
State/province [61] 0 0
Galdakano
Country [62] 0 0
Spain
State/province [62] 0 0
La Coruña
Country [63] 0 0
Spain
State/province [63] 0 0
Las Palmas
Country [64] 0 0
Spain
State/province [64] 0 0
Lugo
Country [65] 0 0
Spain
State/province [65] 0 0
Madrid
Country [66] 0 0
Spain
State/province [66] 0 0
Malaga
Country [67] 0 0
Spain
State/province [67] 0 0
Valencia
Country [68] 0 0
United Kingdom
State/province [68] 0 0
Cambridgeshire
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Essex
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Glamorgan
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Lancashire
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Fleetwood

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents



Results not provided in https://clinicaltrials.gov/study/NCT00479739